

**An Important Message from  
The Texas Health and Human Services Commission (HHSC)**

**Change in Preferred Drug List Status for Glucocorticoids, Inhaled Drug  
Class Takes Effect Dec. 15**

**Background:**

The manufacturer of the brand name Flovent HFA and Flovent Diskus products confirmed that they will discontinue these products on Dec. 31, 2023, and some supplies of the products will remain available until early 2024. In response, HHSC will remove the non-preferred status from the generic fluticasone HFA and Qvar products on the preferred drug list (PDL).

**Key Details:**

Due to this discontinuation, HHSC will remove the non-preferred status from the generic fluticasone HFA and Qvar products below on the PDL. The preferred status of the brand name Flovent HFA and Flovent Diskus will not change. The change will allow providers to prescribe the generic fluticasone HFA and Qvar products without requiring a PDL prior authorization and continue accessing necessary medication for clients.

HHSC will remove the non-preferred status for the following drugs, effective Dec. 15, 2023, and the change will appear in the daily formulary file. **UnitedHealthcare Community Plan of Texas (UHC)** must make this change by Dec. 19, 2023.

NDC	Drug Name
66993007896	FLUTICASONE PROP HFA 44 MCG
66993007996	FLUTICASONE PROP HFA 110 MCG
66993008096	FLUTICASONE PROP HFA 220 MCG
59310030240	QVAR REDHALER 40 MCG
59310030480	QVAR REDHALER 80 MCG

**Questions?**

Please contact your physician advocate or call UnitedHealthcare Provider Services at 888-887-9003, 8 a.m.–6 p.m. CT, Monday–Friday.